中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

598 records (took 0.032 seconds)

    IDENTIFICATION OF COMPOUNDS THAT TARGET THE RNA-BINDING PROTEIN TIA-1 AN IMPORTANT REGULATOR OF STRESS VULNERABILITY IN BOTH MICE AND HUMANS
    4.
    发明申请
    IDENTIFICATION OF COMPOUNDS THAT TARGET THE RNA-BINDING PROTEIN TIA-1 AN IMPORTANT REGULATOR OF STRESS VULNERABILITY IN BOTH MICE AND HUMANS 审中-公开
    靶向RNA结合蛋白TIA-1成为小鼠和人类应激易感性重要调节因子的化合物的鉴定

    公开(公告)号：WO2017218697A1

    公开(公告)日：2017-12-21

    申请号：PCT/US2017/037544

    申请日：2017-06-14

    Applicant: THE TRUSTEES COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

    Inventor： RAYMAN, Joseph, B. ,  KANDEL, Eric, R.

    IPC: A61K38/17 ,  C07K14/435 ,  C07K14/47 ,  G01N33/68

    CPC classification number: C07K14/47 ,  A61K31/375 ,  A61K31/5365 ,  A61K31/65 ,  C07K14/435 ,  G01N33/542

    Abstract: This invention provides a method of ameliorating the symptoms of, or treating post-traumatic stress disorder in a mammal, the method comprising administering to the mammal an effective amount of a compound that upregulates TIA-1 multimerization. This invention also provides a method of ameliorating the symptoms of, or treating post-traumatic stress disorder in a mammal, the method comprising administering to the mammal an effective amount of a compound that inhibits TIA-1 multimerization. This invention also provides a method for determining whether a predetermined compound upregulates or inhibits TIA-1 multimerization, using fluoresence resonance energy transfer (FRET), the method comprising: expressing recombinant TIA-CFP and TIA-YFP; exposing the recombinant TIA-CFP and TIA-YFP to such predetermined compound; exciting the TIA-CFP with a laser; and measuring the fluorescence of TIA-YFP, wherein an increase in fluorescence relative to TIA-CFP and TIA-YFP not exposed to the predetermined compound indicates that the predetermined compound upregulates TIA-1 multimerization and a decrease in fluorescence relative to TIA-CFP and TIA-YFP not exposed to the predetermined compound indicates that the predetermined compound inhibits TIA-1 multimerization.

    Abstract translation: 本发明提供了改善哺乳动物的症状或治疗创伤后应激障碍的方法，所述方法包括给哺乳动物施用有效量的上调TIA-1多聚化作用的化合物。 本发明还提供了改善哺乳动物的症状或治疗创伤后应激障碍的方法，该方法包括给哺乳动物施用有效量的抑制TIA-1多聚化作用的化合物。 本发明还提供了使用荧光共振能量转移（FRET）确定预定化合物是否上调或抑制TIA-1多聚化的方法，所述方法包括：表达重组TIA-CFP和TIA-YFP; 将重组TIA-CFP和TIA-YFP暴露于这种预定化合物; 用激光激发TIA-CFP; 并测量TIA-YFP的荧光，其中相对于未暴露于预定化合物的TIA-CFP和TIA-YFP的荧光增加表明预定化合物相对于TIA-CFP上调TIA-1多聚化和荧光下降，并且 未暴露于预定化合物的TIA-YFP表明预定化合物抑制TIA-1多聚化。

    METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE
    5.
    发明申请
    METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE 审中-公开
    治疗早期DUPUYTREN'S疾病的方法

    公开(公告)号：WO2017177021A1

    公开(公告)日：2017-10-12

    申请号：PCT/US2017/026382

    申请日：2017-04-06

    Applicant: 180 THERAPEUTICS LP

    Inventor： NANCHAHAL, Jagdeep ,  LARSEN, Glenn R. ,  FELDMANN, Marc

    IPC: A61K39/395 ,  A61K39/44 ,  A61K49/16

    Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren' s disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.

    Abstract translation: 本发明提供了治疗患有早期Dupuytren病的个体的方法，其特征在于个体手上存在一个或多个结节，该方法包括向每个结节中注射药物组合物，所述药物组合物包含 有效治疗个体的抗人TNFα抗体或其片段的量，其中所述药物组合物呈液体形式并且将0.1ml至0.6ml的组合物注射到每个结节中。 本发明还提供了用于执行上述方法的预填充注射器。

    COMBINATION OF LAQUINIMOD AND PRIDOPIDINE TO TREAT MULTIPLE SCLEROSIS
    6.
    发明申请
    COMBINATION OF LAQUINIMOD AND PRIDOPIDINE TO TREAT MULTIPLE SCLEROSIS 审中-公开
    LAQUINIMOD和PRIDOPIDINE治疗多发性硬化症的联合

    公开(公告)号：WO2017048457A1

    公开(公告)日：2017-03-23

    申请号：PCT/US2016/047788

    申请日：2016-08-19

    Applicant: TEVA PHARMACEUTICALS INDUSTRIES LTD. ,  TEVA PHARMACEUTICALS USA, INC. ,  GEVA, Michal ,  KAYE, Joel

    Inventor： GEVA, Michal ,  KAYE, Joel

    IPC: A61K31/451 ,  A61K31/4704

    CPC classification number: A61K31/451 ,  A61K31/4704 ,  A61K2300/00

    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS) comprising administering to the subject laquinimod as an add-on to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a subject afflicted with MS or presenting CIS. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a subject afflicted with MS or presenting CIS. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a subject afflicted with MS or presenting CIS.

    Abstract translation: 本发明提供了治疗患有多发性硬化症（MS）或呈现临床分离综合征（CIS）的受试者的方法，其包括向所述受试者的拉喹莫德作为与所述阿维肽的附加物或与其结合施用。 本发明还提供一种包含药物组合物和药物组合物，其包含用于治疗患有MS或显示CIS的受试者的拉喹莫德和格列方啶。 本发明还提供了用作附加疗法的拉喹莫德或与治疗患有MS或呈现CIS的受试者的格列吡啶的组合。 本发明进一步提供了用于治疗患有MS或呈现CIS的受试者的组合的拉喹莫德和派多定的用途。

    SELECT SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE
    8.
    发明申请
    SELECT SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE 审中-公开
    选择单核苷酸多态性对乙酰胆碱反应的预测

    公开(公告)号：WO2016172124A1

    公开(公告)日：2016-10-27

    申请号：PCT/US2016/028316

    申请日：2016-04-19

    Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  GROSSMAN, Iris ,  HAYDEN, Michael ,  ROSS, Colin, James Douglas ,  LAIFENFELD, Daphna ,  DAVIS, Matthew

    Inventor： GROSSMAN, Iris ,  HAYDEN, Michael ,  ROSS, Colin, James Douglas ,  LAIFENFELD, Daphna ,  DAVIS, Matthew

    IPC: A61K38/02 ,  C12Q1/68

    CPC classification number: C12Q1/6883 ,  A61K9/0019 ,  A61K38/02 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

    Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent, with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: rs1894408, kgp7747883, kgp6599438, rs10162089, rs16886004, kgp8110667, kgp8817856, kgp24415534, kgp6214351 and rs759458, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of kgp8110667, rs10162089, rs759458 and kgp6214351, or one or more G alleles at the location of kgp24415534, kgp6599438, kgp7747883, kgp8817856, rs16886004 and rs1894408; and iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.

    Abstract translation: 本发明提供了一种用多种硬化症或单一临床攻击治疗患有多发性硬化的人类受试者的方法，所述多发性硬化症包括含有醋酸格拉默和药学上可接受的载体的药物组合物，包括以下步骤：（i）确定 对应于选自以下的一个或多个单核苷酸多态性（SNP）的位置的对象：rs1894408，kgp7747883，kgp6599438，rs10162089，rs16886004，kgp8110667，kgp8817856，kgp24415534，kgp6214351和rs759458，（ii）鉴定 该受试者作为乙酸格拉默的预测应答者，如果受试者的基因型在kgp8110667，rs10162089，rs759458和kgp6214351的位置包含一个或多个A等位基因，或位于kgp24415534，kgp6599438，kgp7747883，kgp8817856的一个或多个G等位基因 ，rs16886004和rs1894408; 以及iii）仅当所述受试者被鉴定为乙酸格拉默的预测应答者时，向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

Patent Agency Ranking